

Coloplast Annual General Meeting

2022/23

Jürgen | User of ostomy products



Chairman of the Board

Lars Rasmussen

Board of Directors

Other shareholder-elected Board members



Annette Brüls



Carsten Hellmann



Marianne Wiinholt



Jette Nygaard-Andersen

Board of Directors

Employee-elected Board members



Thomas Barfod



Roland Vendelbo Pedersen



Nikolaj Kyhe Gundersen

Executive Leadership Team



Kristian Villumsen
President & CEO



Nicolai Buhl Andersen
Executive Vice
President, Innovation



Anders Lonning-Skovgaard
Executive Vice President &
CFO



Paul Marcun
Executive Vice
President, Growth



Allan Rasmussen
Executive Vice President,
Global Operations



Dorte Rønnau
Senior Vice President,
People & Culture

Coloplast Annual General Meeting

2022/23

Eva | catheter user

Jürgen
Brüger of stomiprodukter

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

- 1. Report by the Board of Directors**
- 2. Presentation and approval of the Annual Report**
- 3. Resolution on the distribution of profit**
- 4. Presentation and approval of the Remuneration Report**
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Chairman of the Board

Lars Rasmussen

This year, Coloplast helped more than
2,000,000 people with intimate healthcare needs



Jason | catheter user

Solid performance despite external challenges

Organic
growth

8%

EBIT margin

28%*

Return on
invested capital

17%**

*before special items

**before special items after tax



Strive25 – focus on innovation and growth





kerecis



kerecis



Atos

Breathing-Speaking-Living
atosmedical.com

Strive25 – focus on innovation and growth



Strive25 - Innovation



Solid progress within innovation



Luja™



Heylo™

**Personalised
Care**

Strive25 - Innovation




Strive25 - Growth



Strive25 - Sustainability



Coloplast has set ambitious 2030 targets for sustainability



Strive25 – Efficiency



Strive25 – Leadership, culture and organisation



Key ratios 2022/23

Mio. kroner	2022/23	2021/22	Change
Net revenue	24,500	22,579	9%
Gross margin	67%	69%	-2 pp
Operating profit (EBIT)	6,845*	6,910*	-1%
Operating margin (EBIT margin)	28%*	31%*	-3 pp
Net profit for the year	4,783	4,706	2%
ROIC after tax	17%*	27%*	-10 pp
Free cash flow	-4,731	-6,660	29%
Net interest-bearing debt	18,660	18,091	3%

*Before special items

Organic growth rates



8%



7%



10%*



7%




10%

*organic growth for 8 months




Bent | user of laryngectomy products

Sales growth per region



Operating profit (EBIT)



- Operating profit (EBIT) before special items (DKK million)
- Operating margin (EBIT, %) before special items




Profit 2022/23

Net profit for the year	DKK 4,783m
Total assets	DKK 48,159m
Equity	DKK 17,299m
Free cash flow for the year	DKK -4,731m
Dividend DKK 21.00 per share	DKK 4,657m
Pay-out ratio	97%



Share price development



Outlook and guidance for 2023/24



We expect Capex of 1.4bn in DKK.

The effective tax rate is expected to be around 22%.

*including Kerecis

Coloplast Annual General Meeting

2022/23

Eva | catheter user

Jürgen
Brüger of stomiprodukter

Agenda

- 1. Report by the Board of Directors**
- 2. Presentation and approval of the Annual Report**
- 3. Resolution on the distribution of profit**
- 4. Presentation and approval of the Remuneration Report**
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
- 5. Approval of the remuneration of the Board of Directors**
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

5. Approval of the remuneration of the Board of Directors

The Board proposes that the remuneration for the Board for the financial year 2023/24 is:

- Ordinary members of the Board are remunerated with a base fee of DKK 450,000.
- The Deputy Chairman of the Board is remunerated with a fee of DKK 787,500, i.e., 1.75 times the base fee.
- The Chairman of the Board is remunerated with DKK 1,350,000, i.e., 3 times the base fee.

The Board proposes that the remuneration for the financial year 2023/24 for ordinary members of the Audit Committee is DKK 240,000, and the remuneration for the Chairman of the Audit Committee is DKK 430,000.

The Board proposes that the remuneration for the financial year 2023/24 for ordinary members of the Remuneration and Nomination Committee is DKK 150,000, and the remuneration for the Chairman of the Remuneration and Nomination Committee is DKK 250,000.

The remuneration for the Board and committees remains unchanged compared to the financial year 2022/23.

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
- 6. Proposals from the Board of Directors**
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

6.1 – 6.3 Indemnification of Board Members, Amendment of Articles of Association, and Update of Remuneration Policy

The board proposes that the annual general meeting adopts an updated indemnification scheme for members of the board, as further described in the notice of the annual general meeting. As a consequence of the proposal, the board also suggests updating the company's remuneration policy and inserting a new article 16 into the company's articles of association, as follows:

§ 16

The Company has established an indemnification scheme for members of its Board of Directors. Under the indemnification scheme, the Company shall indemnify members of the Board of Directors from and against any losses incurred by members of the Board of Directors arising out of any claims raised by any third party (other than Coloplast group companies) based on such members of the Board of Directors' discharge of their duties as members of the Board of Directors. Excluded from indemnification under the scheme are any losses relating to liability incurred by a member of the Board of Directors arising out of such member's fraud, criminal offences, willful misconduct or, to the extent not indemnifiable under Danish law, gross negligence. Indemnification under the scheme shall be secondary to coverage under the directors' and officers' liability insurance, as applicable from time to time, and the Company may thus indemnify for losses, which are not covered wholly or partly by the directors' and officers' liability insurance. The Board of Directors stipulates the provisions on the implementation and administration of the indemnification scheme.

6.4. Authorization to the Board of Directors to acquire treasury shares

The Board of Directors proposes that the company's Board of Directors is authorised to allow the company to acquire treasury shares, in one or more stages, for a nominal value of up to DKK 22,820,000 (corresponding to 10% of the company's share capital), provided that the company's total holding of treasury shares does not exceed 10% of the share capital at any time.

The highest and lowest amount to be paid for the shares is the official quoted price applicable at the time of acquisition of the company's B-shares +/- 10%.

This authorisation is valid until December 6, 2028.

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
- 7. Election of members to the Board of Directors**
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

7. Election of members to the Board of Directors

The Board of Directors proposes re-election of the following members:

- Lars Rasmussen
- Niels Peter Louis-Hansen
- Annette Bröls
- Carsten Hellmann
- Jette Nygaard-Andersen
- Marianne Wiinholt

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
- 8. Election of auditors**
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
- 9. Authorisation to the chairman of the meeting**
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
- 10. Any other business**



Coloplast